A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-06

AUTHORS

Marc Evans, Phil McEwan, Richard O’Shea, Lindsay George

ABSTRACT

INTRODUCTION: While incretin-based therapies have been compared in clinical trials, data comparing their relative efficacy in clinical practice remain limited, particularly when prescribed according to clinical guidelines. This study assessed the clinical and cost-effectiveness of, and patient preference for, incretin-based therapies initiated according to the National Institute for Health and Clinical Excellence (NICE) recommendations in UK clinical practice. METHODS: In a retrospective chart audit, anonymized data were collected for patients receiving incretin-based therapy according to NICE recommendations in clinical practice in Wales, UK. Parameters assessed included glycated hemoglobin (HbA1c), weight, achievement of NICE treatment continuation criteria, adverse events, treatment discontinuation, and drug cost-effectiveness based on observed treatment effects. Treatment preference for a dipeptidyl peptidase-4 inhibitor (DPP-4i) or glucagon-like peptide-1 receptor agonist (GLP-1RA) was assessed prospectively. RESULTS: Patients (1,114) were followed-up for a median of 48 weeks (256 received liraglutide, 148 received exenatide twice daily, and 710 received a DPP-4i). Liraglutide reduced HbA1c significantly more versus exenatide or DPP-4i (both P < 0.05). Weight changes were similar for GLP-1RAs but significantly greater vs. DPP-4is (both P < 0.05). NICE treatment continuation criteria were met by 32% and 24% of liraglutide 1.2 mg- and exenatide-treated patients (≥1% HbA1c reduction, ≥3% weight loss), and 61% of DPP-4i-treated patients (≥0.5% HbA1c reduction). Life-years gained per patient were 0.12, 0.08, and 0.07, and costs per quality-adjusted life-year were £16,505, £16,648, and £20,661 for liraglutide, exenatide, and DPP-4is, respectively. More patients (62.5%) preferred the GLP-1RA profile, with these patients having higher baseline body mass index score and HbA1c values, and longer diabetes duration than those preferring the DPP-4i profile. CONCLUSION: When prescribed according to NICE recommendations, incretin-based therapies are both clinically and cost-effective options, with liraglutide providing greatest HbA1c reductions. Greater body weight reductions occur with GLP-1RAs compared with DPP-4is. Patients with higher baseline HbA1c and longer diabetes duration prefer a GLP-1RA profile versus a DPP-4i. More... »

PAGES

27-40

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-012-0015-6

DOI

http://dx.doi.org/10.1007/s13300-012-0015-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1029222060

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23225378


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University Hospital Llandough", 
          "id": "https://www.grid.ac/institutes/grid.416025.4", 
          "name": [
            "University Hospital Llandough, Penlan Road, Llandough, Penarth, South Glamorgan, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Evans", 
        "givenName": "Marc", 
        "id": "sg:person.01167546340.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167546340.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Swansea University", 
          "id": "https://www.grid.ac/institutes/grid.4827.9", 
          "name": [
            "Swansea University, Singleton Park, Swansea, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McEwan", 
        "givenName": "Phil", 
        "id": "sg:person.01346767345.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346767345.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiff University", 
          "id": "https://www.grid.ac/institutes/grid.5600.3", 
          "name": [
            "University of Wales College of Medicine, Heath Park, Cardiff Heath Park, Cardiff, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "O\u2019Shea", 
        "givenName": "Richard", 
        "id": "sg:person.01303774740.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303774740.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Hospital Llandough", 
          "id": "https://www.grid.ac/institutes/grid.416025.4", 
          "name": [
            "University Hospital Llandough, Penlan Road, Llandough, Penarth, South Glamorgan, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "George", 
        "givenName": "Lindsay", 
        "id": "sg:person.015453446135.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015453446135.09"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/j.1742-1241.2011.02656.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002864615"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(09)60659-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010613532"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1463-1326.2010.01330.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017466989"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.beem.2009.03.008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018422376"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/ppa.s14477", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022637759"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc09-2260", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023875813"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1463-1326.2011.01428.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026933014"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.diabres.2010.07.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028681036"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/03007990802418851", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032159351"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1464-5491.2010.03074.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033856347"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diabetes.53.5.1187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035777111"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-004-1527-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036304902", 
          "https://doi.org/10.1007/s00125-004-1527-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-004-1527-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036304902", 
          "https://doi.org/10.1007/s00125-004-1527-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/14651858.cd006423.pub2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043704254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(10)60307-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047129639"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-012-2534-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048718893", 
          "https://doi.org/10.1007/s00125-012-2534-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-012-2534-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048718893", 
          "https://doi.org/10.1007/s00125-012-2534-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.298.2.194", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053622743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jc.2004-2460", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064288235"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-06", 
    "datePublishedReg": "2013-06-01", 
    "description": "INTRODUCTION: While incretin-based therapies have been compared in clinical trials, data comparing their relative efficacy in clinical practice remain limited, particularly when prescribed according to clinical guidelines. This study assessed the clinical and cost-effectiveness of, and patient preference for, incretin-based therapies initiated according to the National Institute for Health and Clinical Excellence (NICE) recommendations in UK clinical practice.\nMETHODS: In a retrospective chart audit, anonymized data were collected for patients receiving incretin-based therapy according to NICE recommendations in clinical practice in Wales, UK. Parameters assessed included glycated hemoglobin (HbA1c), weight, achievement of NICE treatment continuation criteria, adverse events, treatment discontinuation, and drug cost-effectiveness based on observed treatment effects. Treatment preference for a dipeptidyl peptidase-4 inhibitor (DPP-4i) or glucagon-like peptide-1 receptor agonist (GLP-1RA) was assessed prospectively.\nRESULTS: Patients (1,114) were followed-up for a median of 48\u00a0weeks (256 received liraglutide, 148 received exenatide twice daily, and 710 received a DPP-4i). Liraglutide reduced HbA1c significantly more versus exenatide or DPP-4i (both P\u00a0<\u00a00.05). Weight changes were similar for GLP-1RAs but significantly greater vs. DPP-4is (both P\u00a0<\u00a00.05). NICE treatment continuation criteria were met by 32% and 24% of liraglutide 1.2\u00a0mg- and exenatide-treated patients (\u22651% HbA1c reduction,\u00a0\u22653% weight loss), and 61% of DPP-4i-treated patients (\u22650.5% HbA1c reduction). Life-years gained per patient were 0.12, 0.08, and 0.07, and costs per quality-adjusted life-year were \u00a316,505, \u00a316,648, and \u00a320,661 for liraglutide, exenatide, and DPP-4is, respectively. More patients (62.5%) preferred the GLP-1RA profile, with these patients having higher baseline body mass index score and HbA1c values, and longer diabetes duration than those preferring the DPP-4i profile.\nCONCLUSION: When prescribed according to NICE recommendations, incretin-based therapies are both clinically and cost-effective options, with liraglutide providing greatest HbA1c reductions. Greater body weight reductions occur with GLP-1RAs compared with DPP-4is. Patients with higher baseline HbA1c and longer diabetes duration prefer a GLP-1RA profile versus a DPP-4i.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s13300-012-0015-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "4"
      }
    ], 
    "name": "A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice", 
    "pagination": "27-40", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "8b35e30098248396e6f280f4776e7c6016ed37f5b2bf2a3412a319d809597c1a"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23225378"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101539025"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-012-0015-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1029222060"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-012-0015-6", 
      "https://app.dimensions.ai/details/publication/pub.1029222060"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T02:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8700_00000522.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs13300-012-0015-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-012-0015-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-012-0015-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-012-0015-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-012-0015-6'


 

This table displays all metadata directly associated to this object as RDF triples.

149 TRIPLES      21 PREDICATES      46 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-012-0015-6 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N3e4603a57c1b43cca48131acdbd15b53
4 schema:citation sg:pub.10.1007/s00125-004-1527-z
5 sg:pub.10.1007/s00125-012-2534-0
6 https://doi.org/10.1001/jama.298.2.194
7 https://doi.org/10.1002/14651858.cd006423.pub2
8 https://doi.org/10.1016/j.beem.2009.03.008
9 https://doi.org/10.1016/j.diabres.2010.07.006
10 https://doi.org/10.1016/s0140-6736(09)60659-0
11 https://doi.org/10.1016/s0140-6736(10)60307-8
12 https://doi.org/10.1111/j.1463-1326.2010.01330.x
13 https://doi.org/10.1111/j.1463-1326.2011.01428.x
14 https://doi.org/10.1111/j.1464-5491.2010.03074.x
15 https://doi.org/10.1111/j.1742-1241.2011.02656.x
16 https://doi.org/10.1185/03007990802418851
17 https://doi.org/10.1210/jc.2004-2460
18 https://doi.org/10.2147/ppa.s14477
19 https://doi.org/10.2337/dc09-2260
20 https://doi.org/10.2337/diabetes.53.5.1187
21 schema:datePublished 2013-06
22 schema:datePublishedReg 2013-06-01
23 schema:description INTRODUCTION: While incretin-based therapies have been compared in clinical trials, data comparing their relative efficacy in clinical practice remain limited, particularly when prescribed according to clinical guidelines. This study assessed the clinical and cost-effectiveness of, and patient preference for, incretin-based therapies initiated according to the National Institute for Health and Clinical Excellence (NICE) recommendations in UK clinical practice. METHODS: In a retrospective chart audit, anonymized data were collected for patients receiving incretin-based therapy according to NICE recommendations in clinical practice in Wales, UK. Parameters assessed included glycated hemoglobin (HbA1c), weight, achievement of NICE treatment continuation criteria, adverse events, treatment discontinuation, and drug cost-effectiveness based on observed treatment effects. Treatment preference for a dipeptidyl peptidase-4 inhibitor (DPP-4i) or glucagon-like peptide-1 receptor agonist (GLP-1RA) was assessed prospectively. RESULTS: Patients (1,114) were followed-up for a median of 48 weeks (256 received liraglutide, 148 received exenatide twice daily, and 710 received a DPP-4i). Liraglutide reduced HbA1c significantly more versus exenatide or DPP-4i (both P < 0.05). Weight changes were similar for GLP-1RAs but significantly greater vs. DPP-4is (both P < 0.05). NICE treatment continuation criteria were met by 32% and 24% of liraglutide 1.2 mg- and exenatide-treated patients (≥1% HbA1c reduction, ≥3% weight loss), and 61% of DPP-4i-treated patients (≥0.5% HbA1c reduction). Life-years gained per patient were 0.12, 0.08, and 0.07, and costs per quality-adjusted life-year were £16,505, £16,648, and £20,661 for liraglutide, exenatide, and DPP-4is, respectively. More patients (62.5%) preferred the GLP-1RA profile, with these patients having higher baseline body mass index score and HbA1c values, and longer diabetes duration than those preferring the DPP-4i profile. CONCLUSION: When prescribed according to NICE recommendations, incretin-based therapies are both clinically and cost-effective options, with liraglutide providing greatest HbA1c reductions. Greater body weight reductions occur with GLP-1RAs compared with DPP-4is. Patients with higher baseline HbA1c and longer diabetes duration prefer a GLP-1RA profile versus a DPP-4i.
24 schema:genre research_article
25 schema:inLanguage en
26 schema:isAccessibleForFree true
27 schema:isPartOf Nbd44f92011704d698395b3ed52137f8d
28 Nea1352499ade4cc9a1785e26819f18ca
29 sg:journal.1044057
30 schema:name A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice
31 schema:pagination 27-40
32 schema:productId N14ff8fd26ca340e69f7fcfe683a61503
33 N4b27677a21c14bb0b06d3aa15b165bc8
34 N591256cc3cbb47dc88ea48716c9bdb38
35 N5e549db9017b40919b966bdeef4ad7d2
36 Nc9ad1f4f7145445b81b64d1a6c8dfb22
37 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029222060
38 https://doi.org/10.1007/s13300-012-0015-6
39 schema:sdDatePublished 2019-04-11T02:08
40 schema:sdLicense https://scigraph.springernature.com/explorer/license/
41 schema:sdPublisher Nbf66599d75284091adabb3cf675f7337
42 schema:url http://link.springer.com/10.1007%2Fs13300-012-0015-6
43 sgo:license sg:explorer/license/
44 sgo:sdDataset articles
45 rdf:type schema:ScholarlyArticle
46 N14ff8fd26ca340e69f7fcfe683a61503 schema:name nlm_unique_id
47 schema:value 101539025
48 rdf:type schema:PropertyValue
49 N3e4603a57c1b43cca48131acdbd15b53 rdf:first sg:person.01167546340.80
50 rdf:rest N8ad8ab52f3c04875972a164e40e91deb
51 N490a2d4431f84a5b8174984a223e8778 rdf:first sg:person.015453446135.09
52 rdf:rest rdf:nil
53 N4b27677a21c14bb0b06d3aa15b165bc8 schema:name doi
54 schema:value 10.1007/s13300-012-0015-6
55 rdf:type schema:PropertyValue
56 N591256cc3cbb47dc88ea48716c9bdb38 schema:name pubmed_id
57 schema:value 23225378
58 rdf:type schema:PropertyValue
59 N5e549db9017b40919b966bdeef4ad7d2 schema:name readcube_id
60 schema:value 8b35e30098248396e6f280f4776e7c6016ed37f5b2bf2a3412a319d809597c1a
61 rdf:type schema:PropertyValue
62 N8ad8ab52f3c04875972a164e40e91deb rdf:first sg:person.01346767345.38
63 rdf:rest N9ea2110b49994f308adb1a87b94edd76
64 N9ea2110b49994f308adb1a87b94edd76 rdf:first sg:person.01303774740.77
65 rdf:rest N490a2d4431f84a5b8174984a223e8778
66 Nbd44f92011704d698395b3ed52137f8d schema:volumeNumber 4
67 rdf:type schema:PublicationVolume
68 Nbf66599d75284091adabb3cf675f7337 schema:name Springer Nature - SN SciGraph project
69 rdf:type schema:Organization
70 Nc9ad1f4f7145445b81b64d1a6c8dfb22 schema:name dimensions_id
71 schema:value pub.1029222060
72 rdf:type schema:PropertyValue
73 Nea1352499ade4cc9a1785e26819f18ca schema:issueNumber 1
74 rdf:type schema:PublicationIssue
75 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
76 schema:name Medical and Health Sciences
77 rdf:type schema:DefinedTerm
78 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
79 schema:name Clinical Sciences
80 rdf:type schema:DefinedTerm
81 sg:journal.1044057 schema:issn 1869-6953
82 1869-6961
83 schema:name Diabetes Therapy
84 rdf:type schema:Periodical
85 sg:person.01167546340.80 schema:affiliation https://www.grid.ac/institutes/grid.416025.4
86 schema:familyName Evans
87 schema:givenName Marc
88 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167546340.80
89 rdf:type schema:Person
90 sg:person.01303774740.77 schema:affiliation https://www.grid.ac/institutes/grid.5600.3
91 schema:familyName O’Shea
92 schema:givenName Richard
93 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303774740.77
94 rdf:type schema:Person
95 sg:person.01346767345.38 schema:affiliation https://www.grid.ac/institutes/grid.4827.9
96 schema:familyName McEwan
97 schema:givenName Phil
98 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346767345.38
99 rdf:type schema:Person
100 sg:person.015453446135.09 schema:affiliation https://www.grid.ac/institutes/grid.416025.4
101 schema:familyName George
102 schema:givenName Lindsay
103 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015453446135.09
104 rdf:type schema:Person
105 sg:pub.10.1007/s00125-004-1527-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1036304902
106 https://doi.org/10.1007/s00125-004-1527-z
107 rdf:type schema:CreativeWork
108 sg:pub.10.1007/s00125-012-2534-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048718893
109 https://doi.org/10.1007/s00125-012-2534-0
110 rdf:type schema:CreativeWork
111 https://doi.org/10.1001/jama.298.2.194 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053622743
112 rdf:type schema:CreativeWork
113 https://doi.org/10.1002/14651858.cd006423.pub2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043704254
114 rdf:type schema:CreativeWork
115 https://doi.org/10.1016/j.beem.2009.03.008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018422376
116 rdf:type schema:CreativeWork
117 https://doi.org/10.1016/j.diabres.2010.07.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028681036
118 rdf:type schema:CreativeWork
119 https://doi.org/10.1016/s0140-6736(09)60659-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010613532
120 rdf:type schema:CreativeWork
121 https://doi.org/10.1016/s0140-6736(10)60307-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047129639
122 rdf:type schema:CreativeWork
123 https://doi.org/10.1111/j.1463-1326.2010.01330.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1017466989
124 rdf:type schema:CreativeWork
125 https://doi.org/10.1111/j.1463-1326.2011.01428.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1026933014
126 rdf:type schema:CreativeWork
127 https://doi.org/10.1111/j.1464-5491.2010.03074.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1033856347
128 rdf:type schema:CreativeWork
129 https://doi.org/10.1111/j.1742-1241.2011.02656.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1002864615
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1185/03007990802418851 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032159351
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1210/jc.2004-2460 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064288235
134 rdf:type schema:CreativeWork
135 https://doi.org/10.2147/ppa.s14477 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022637759
136 rdf:type schema:CreativeWork
137 https://doi.org/10.2337/dc09-2260 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023875813
138 rdf:type schema:CreativeWork
139 https://doi.org/10.2337/diabetes.53.5.1187 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035777111
140 rdf:type schema:CreativeWork
141 https://www.grid.ac/institutes/grid.416025.4 schema:alternateName University Hospital Llandough
142 schema:name University Hospital Llandough, Penlan Road, Llandough, Penarth, South Glamorgan, UK
143 rdf:type schema:Organization
144 https://www.grid.ac/institutes/grid.4827.9 schema:alternateName Swansea University
145 schema:name Swansea University, Singleton Park, Swansea, UK
146 rdf:type schema:Organization
147 https://www.grid.ac/institutes/grid.5600.3 schema:alternateName Cardiff University
148 schema:name University of Wales College of Medicine, Heath Park, Cardiff Heath Park, Cardiff, UK
149 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...